Author

Marco Barreca

Observed name: BARRECA, MARCO

Institutions: Fondazione Michelangelo, European Institute of Oncology, University of Milano-Bicocca

Observed institutions: Fondazione Michelangelo, IRCCS Ospedale San Raffaele, European Institute of Oncology, University of Milano-Bicocca

ORCID: 0000-0002-9152-236X

Observed ORCID: 0000-0002-9152-236X

OpenAlex ID: A5059151171

Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response

2023 · Carlo Bosi, Áron Bartha, et al. · European Journal of Cancer · 59

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy

2023 · Luca Licata, Marco Barreca, et al. · British Journal of Cancer · 11

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies

2025 · Maurizio Callari, Matteo Dugo, et al. · Nature Communications · 10

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy

2026 · Giulia Notini, Barbara Galbardi, et al. · npj Precision Oncology · 4

Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment

2022 · Maurizio Callari, Marco Barreca, et al. · Cancer Research · 3

Development and validation of a gene expression-based Breast Cancer Purity Score

2024 · Marco Barreca, Matteo Dugo, et al. · npj Precision Oncology · 2

varianTalker: a Nextflow Framework for Scalable, Portable and Clinically Oriented Variant Annotation, Prioritization, and Review

2026 · Gianluca A. Mariani, Marco Barreca, et al. · Research Square

Deciphering the Tumor Microenvironment Composition Using Bulk Transcriptomics: A Guide to Recent Advances and Open Challenges

2025 · Sotiris Ouzounis, Donya Zojaji, et al. · Methods in molecular biology

Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial

2022 · Maurizio Callari, Chiun-Sheng Huang, et al. · Cancer Research

Multidimensional data integration to capture intrinsic and extrinsic mechanisms driving treatment benefit in breast cancer

· BARRECA, MARCO · BOA (University of Milano-Bicocca)

Works count: 13

Citation count: 89

H-index: 4

I10-index: 3